3 results
Approved WMOWill not start
To examine the effect of L-dopa addition to optimal D2-blocking antipsychotic treatment on positive symptoms, negative symptoms, cognitive symptoms and extrapyramidal symptoms in schizophrenia.
Approved WMOWill not start
Objectives:Primary objectiveTo evaluate the long-term safety and tolerability of padsevonil (PSL) administered at individualized doses between 100 mg/day and 800 mg/day as adjunctive treatment for subjects with focal-onset seizures and drug-…
Approved WMOWill not start
Objectives:Primary objective:To evaluate the efficacy of the 3 selected dose regimens of Padsevonil (PSL) administered concomitantly with up to 3 antiepileptic drugs (AEDs) compared with Placebo for treatment of observable focal-onset seizures in…